Document_and_Entity_Informatio
Document and Entity Information | 3 Months Ended | |
Mar. 31, 2014 | 1-May-14 | |
Document And Entity Information | ' | ' |
Entity Registrant Name | 'Regen BioPharma Inc | ' |
Entity Central Index Key | '0001589150 | ' |
Document Type | '10-Q | ' |
Document Period End Date | 30-Sep-13 | ' |
Amendment Flag | 'false | ' |
Current Fiscal Year End Date | '--09-30 | ' |
Is Entity a Well-known Seasoned Issuer? | 'No | ' |
Is Entity a Voluntary Filer? | 'No | ' |
Is Entity's Reporting Status Current? | 'Yes | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Common Stock, Shares Outstanding | ' | 51,910,000 |
Document Fiscal Period Focus | 'Q2 | ' |
Document Fiscal Year Focus | '2014 | ' |
BALANCE_SHEET_Unaudited
BALANCE SHEET (Unaudited) (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
CURRENT ASSETS | ' | ' |
Cash | $122,789 | $115,922 |
Total Current Assets | 122,789 | 115,922 |
TOTAL ASSETS | 122,789 | 115,922 |
Current Liabilities: | ' | ' |
Accounts payable | 833 | 0 |
Accrued payroll taxes | 6,764 | ' |
Total Current Liabilities | 7,597 | 0 |
Total Liabilities | 7,597 | 0 |
STOCKHOLDERS EQUITY (DEFICIT) | ' | ' |
Common Stock ($.0001 par value) 500,000,000 shares authorized; 51,610,000 issued and outstanding as of September 30, 2013 and 51,910,000 shares issued and outstanding March 31, 2014 | 5,191 | 5,161 |
Preferred Stock($.0001 par value) 5,000,000 shares authorized 0 shares issued and outstanding as of September 30, 2013 and March 31, 2014 | 0 | 0 |
Additional Paid in capital | 485,097 | 185,127 |
Contributed Capital | 542,858 | 447,858 |
Retained Earnings (Deficit) accumulated during the development stage | -917,954 | -522,224 |
Total Stockholders' Equity (Deficit) | 115,192 | 115,192 |
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) | $122,789 | $115,922 |
BALANCE_SHEET_Parenthetical
BALANCE SHEET (Parenthetical) (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
Statement of Financial Position [Abstract] | ' | ' |
Common stock, par value (in dollars per share) | $0.00 | $0.00 |
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Common stock, shares issued | 51,910,000 | 51,610,000 |
Common stock, shares outstanding | 51,910,000 | 51,610,000 |
Preferred stock, par value (in dollars per share) | $0.00 | $0.00 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
STATEMENT_OF_OPERATIONS_Unaudi
STATEMENT OF OPERATIONS (Unaudited) (USD $) | 3 Months Ended | 6 Months Ended | 23 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | |
Income Statement [Abstract] | ' | ' | ' | ' | ' |
REVENUES | $0 | $0 | $0 | $0 | $0 |
COST AND EXPENSES | ' | ' | ' | ' | ' |
Research and Development | 8,042 | ' | 13,867 | 5,394 | 39,976 |
General and Administrative | 133,086 | 70,505 | 262,381 | 156,950 | 662,445 |
Consulting and Professional Fees | 28,915 | ' | 79,630 | ' | 140,483 |
Total Costs and Expenses | 170,043 | 70,505 | 355,878 | 162,344 | 842,904 |
OPERATING LOSS | -170,043 | -70,505 | -355,878 | -162,344 | -842,904 |
OTHER INCOME & (EXPENSES) | ' | ' | ' | ' | ' |
Refunds of amounts previously paid | ' | ' | ' | ' | 35,000 |
Capital contribution to parent | -16,158 | ' | -39,852 | ' | -110,050 |
TOTAL OTHER INCOME (EXPENSE) | ' | ' | ' | ' | -75,050 |
NET INCOME (LOSS) | ($186,201) | ($70,505) | ($395,730) | ($162,344) | ($917,954) |
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE | ($0.00) | ($7.05) | ($0.01) | ($16.23) | ' |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING | 51,910,000 | 10,000 | 51,552,253 | 10,000 | ' |
STATEMENT_OF_CASH_FLOWS_Unaudi
STATEMENT OF CASH FLOWS (Unaudited) (USD $) | 6 Months Ended | 23 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' | ' |
Net Income (loss) | ($395,730) | ($162,344) | ($917,954) |
Adjustments to reconcile net Income to net cash | ' | ' | ' |
Common Stock issued for expenses | ' | ' | 70,198 |
Increase (Decrease) in Accounts Payable | 833 | 10,000 | 833 |
Increase (Decrease) in accrued Expenses | 6,764 | ' | 6,764 |
Net Cash Provided by (Used in) Operating Activities | -388,133 | -152,344 | -840,159 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' | ' |
Common Stock issued for Cash | 300,000 | ' | 420,090 |
Increase in Contributed Capital | 95,000 | 162,049 | 542,858 |
Net Cash Provided by (Used in) Financing Activities | 395,000 | 162,049 | 962,948 |
Net Increase (Decrease) in Cash | 6,867 | 9,705 | 122,789 |
Cash at Beginning of Period | 115,922 | 923 | 0 |
Cash at End of Period | $122,789 | $10,628 | $122,789 |
ORGANIZATION_AND_SUMMARY_OF_SI
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Mar. 31, 2014 | |
Accounting Policies [Abstract] | ' |
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ' |
NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc, a Delaware corporation. | |
The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials | |
A. BASIS OF ACCOUNTING | |
The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. | |
B. USE OF ESTIMATES | |
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |
C. DEVELOPMENT STAGE | |
The Company is a development stage company devoting substantially all of its efforts to establish a new business. | |
D. CASH EQUIVALENTS | |
The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. | |
E. PROPERTY AND EQUIPMENT | |
Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized. | |
F. FAIR VALUE OF FINANCIAL INSTRUMENTS | |
Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: | |
Level 1: Quoted prices in active markets for identical assets or liabilities | |
Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. | |
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. | |
G. INCOME TAXES | |
The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. | |
The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31 2014 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. | |
The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. | |
Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. | |
H. BASIC EARNINGS (LOSS) PER SHARE | |
The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. | |
Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. | |
I. ADVERTISING | |
Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended March 31, 2014 and $0 for the twelve months ended September 30, 2013. |
RECENT_ACCOUNTING_PRONOUNCEMEN
RECENT ACCOUNTING PRONOUNCEMENTS | 3 Months Ended |
Mar. 31, 2014 | |
Accounting Changes and Error Corrections [Abstract] | ' |
RECENT ACCOUNTING PRONOUNCEMENTS | ' |
NOTE 2 . RECENT ACCOUNTING PRONOUNCEMENTS | |
The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows. | |
On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. | |
On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: | |
The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. | |
Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. | |
While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. | |
On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. | |
A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements. |
GOING_CONCERN
GOING CONCERN | 3 Months Ended |
Mar. 31, 2014 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
GOING CONCERN | ' |
NOTE 3. GOING CONCERN | |
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 917,954 during the period from April 24, 2012 (inception) through March 31, 2014. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. | |
Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings. |
INCOME_TAXES
INCOME TAXES | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Income Tax Disclosure [Abstract] | ' | ||||
INCOME TAXES | ' | ||||
NOTE 4. INCOME TAXES | |||||
As of March 31, 2014 | |||||
Deferred tax assets: | |||||
Net operating tax carry forwards | $ | 312,104 | |||
Other | -0- | ||||
Gross deferred tax assets | 312,104 | ||||
Valuation allowance | -312,104 | ) | |||
Net deferred tax assets | $ | -0- | |||
As of March 31, 2014 the Company has a Deferred Tax Asset of $312,104 completely attributable to net operating loss carry forwards of approximately $ 917,954 (which expire 20 years from the date the loss was incurred). | |||||
Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0. | |||||
Income tax is calculated at the 34% Federal Corporate Rate. |
RELATED_PARTY_TRANSACTIONS
RELATED PARTY TRANSACTIONS | 3 Months Ended |
Mar. 31, 2014 | |
Related Party Transactions [Abstract] | ' |
RELATED PARTY TRANSACTIONS | ' |
NOTE 5. RELATED PARTY TRANSACTIONS | |
As of March 31, 2014 the Company has received capital contributions from its parent totaling $542,858 and has issued 50,010, 000 common shares to its parent fro aggregate consideration of $20,090. The Company also utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941provided to the Company by Entest BioMedical, Inc. on a month to month basis free of charge. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent. | |
On August 20, 2013 the Company issued 1,500,000 common shares to the holder of one of its parent’s convertible notes (“Parent Convertible Note Holder”) in satisfaction of $70,198 owed by the Company’s parent to the Parent Convertible Note Holder. During the three months ended December 31, 2013 | |
(1) The Company has paid to a creditor of its parent a total of $12,713 of principal indebtedness owed by the Company’s parent | |
(2) The Company has made payments of $4,610 to David Koos in satisfaction of $4,610 of indebtedness owed to David Koos by the Company’s parent | |
(3) The Company has paid $6,369 of expenses incurred by the Company’s parent on its behalf. | |
Between the period beginning September 1, 2013 and ending March 31, 2013 the Company made payments of $28,117 to Entest Biomedical, Inc. on behalf of its parent. | |
During the quarter ended March 31, 2014 the Company has paid $755 of expenses incurred by the Company’s parent on its behalf. |
STOCKHOLDERS_EQUITY
STOCKHOLDERS' EQUITY | 3 Months Ended |
Mar. 31, 2014 | |
Equity [Abstract] | ' |
STOCKHOLDERS' EQUITY | ' |
NOTE 6. STOCKHOLDERS' EQUITY | |
The stockholders' equity section of the Company contains the following classes of capital stock as March 31, 2014: | |
Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 51,910,000 shares issued and outstanding. | |
With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). | |
On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. | |
Preferred Stock, $0.0001 par value, 5,000,000 shares authorized: 0 shares issued and outstanding | |
The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. |
ORGANIZATION_AND_SUMMARY_OF_SI1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
Mar. 31, 2014 | |
Accounting Policies [Abstract] | ' |
BASIS OF ACCOUNTING | ' |
A. BASIS OF ACCOUNTING | |
The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. | |
USE OF ESTIMATES | ' |
B. USE OF ESTIMATES | |
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |
DEVELOPMENT STAGE | ' |
C. DEVELOPMENT STAGE | |
The Company is a development stage company devoting substantially all of its efforts to establish a new business. | |
CASH EQUIVALENTS | ' |
D. CASH EQUIVALENTS | |
The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. | |
PROPERTY AND EQUIPMENT | ' |
E. PROPERTY AND EQUIPMENT | |
Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized. | |
FAIR VALUE OF FINANCIAL INSTRUMENTS | ' |
F. FAIR VALUE OF FINANCIAL INSTRUMENTS | |
Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: | |
Level 1: Quoted prices in active markets for identical assets or liabilities | |
Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. | |
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. | |
INCOME TAXES | ' |
G. INCOME TAXES | |
The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. | |
The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31 2014 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. | |
The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. | |
Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. | |
BASIC EARNINGS (LOSS) PER SHARE | ' |
H. BASIC EARNINGS (LOSS) PER SHARE | |
The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. | |
Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. | |
ADVERTISING | ' |
I. ADVERTISING | |
Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarter ended March 31, 2014 and $0 for the twelve months ended September 30, 2013. |
INCOME_TAXES_Tables
INCOME TAXES (Tables) | 3 Months Ended | ||||
Mar. 31, 2014 | |||||
Income Tax Disclosure [Abstract] | ' | ||||
Deferred tax assets | ' | ||||
As of March 31, 2014 | |||||
Deferred tax assets: | |||||
Net operating tax carry forwards | $ | 312,104 | |||
Other | -0- | ||||
Gross deferred tax assets | 312,104 | ||||
Valuation allowance | -312,104 | ) | |||
Net deferred tax assets | $ | -0- |
ORGANIZATION_AND_SUMMARY_OF_SI2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $) | 3 Months Ended |
Mar. 31, 2014 | |
Accounting Policies [Abstract] | ' |
Valuation allowance | 100.00% |
Incurred advertising expenses | $0 |
GOING_CONCERN_Details_Narrativ
GOING CONCERN (Details Narrative) (USD $) | 3 Months Ended | 6 Months Ended | 23 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' | ' | ' | ' | ' |
Net losses | ($186,201) | ($70,505) | ($395,730) | ($162,344) | ($917,954) |
INCOME_TAXES_Deferred_tax_asse
INCOME TAXES - Deferred tax assets (Details) (USD $) | Mar. 31, 2014 |
Deferred tax assets: | ' |
Net operating tax carry forwards | $312,104 |
Other | 0 |
Gross deferred tax assets | 312,104 |
Valuation allowance | -312,104 |
Net deferred tax assets | $0 |
INCOME_TAXES_Details_Narrative
INCOME TAXES (Details Narrative) (USD $) | 3 Months Ended |
Mar. 31, 2014 | |
Income Tax Disclosure [Abstract] | ' |
Deferred tax asset | $312,104 |
Net loss carryforwards | 917,954 |
Deferred tax assets, net valuation allowance | $0 |
Income tax, Federal rate | 34.00% |
RELATED_PARTY_TRANSACTIONS_Det
RELATED PARTY TRANSACTIONS (Details Narrative) (USD $) | 3 Months Ended | 16 Months Ended | 23 Months Ended | |
Mar. 31, 2014 | Dec. 31, 2013 | Aug. 20, 2013 | Mar. 31, 2014 | |
Related Party Transactions [Abstract] | ' | ' | ' | ' |
Contributions from parent | ' | ' | ' | $542,858 |
Shares issued to Parent for aggregate consideration | ' | ' | 1,500,000 | 50,010,000 |
Shares issued to Parent for aggregate consideration, Amount | ' | ' | 70,198 | 20,090 |
Amount paid to creditor of parent | 28,117 | 12,713 | ' | ' |
Payments to David Koos | ' | 4,610 | ' | ' |
Amount paid in expenses incurred by parent Company | $755 | $6,369 | ' | ' |
STOCKHOLDERS_EQUITY_Details_Na
STOCKHOLDERS' EQUITY (Details Narrative) (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
Equity [Abstract] | ' | ' |
Common stock, par value (in dollars per share) | $0.00 | $0.00 |
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Common stock, shares issued | 51,910,000 | 51,610,000 |
Common stock, shares outstanding | 51,910,000 | 51,610,000 |
Preferred stock, par value (in dollars per share) | $0.00 | $0.00 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |